The summaries are free for public
use. The Chronic Liver Disease
Foundation will continue to add and
archive summaries of articles deemed
relevant to CLDF by the Board of
Trustees and its Advisors.
Abstract Details
Hepatitis C virus (HCV) seroprevalence, RNA detection, and genotype distribution across Florida, 2015-2018
1Center for Immunization and Infection Research in Cancer, Moffitt Cancer Center, Tampa, FL, United States of America; Department of Cancer Epidemiology, Moffitt Cancer Center, Tampa, FL, United States of America.
2Biostatistics and Bioinformatics Shared Resource, Moffitt Cancer Center, Tampa, FL, United States of America.
3Center for Immunization and Infection Research in Cancer, Moffitt Cancer Center, Tampa, FL, United States of America; Department of Health Outcomes and Behavior, Moffitt Cancer Center, Tampa, FL, United States of America.
4Center for Immunization and Infection Research in Cancer, Moffitt Cancer Center, Tampa, FL, United States of America; Department of Health Outcomes and Behavior, Moffitt Cancer Center, Tampa, FL, United States of America; Department of Oncologic Sciences, University of South Florida, Tampa, FL, United States of America; Department of Gastrointestinal Oncology, Moffitt Cancer Center, Tampa, FL, United States of America.
5Department of Health Outcomes and Behavior, Moffitt Cancer Center, Tampa, FL, United States of America; Department of Family Medicine, University of South Florida, Tampa, FL, United States of America.
6Department of Health Outcomes and Biomedical Informatics, College of Medicine, University of Florida, University of Florida Health Cancer Center, Gainesville, FL, United States of America.
7Center for Immunization and Infection Research in Cancer, Moffitt Cancer Center, Tampa, FL, United States of America; Department of Cancer Epidemiology, Moffitt Cancer Center, Tampa, FL, United States of America. Electronic address: anna.giuliano@moffitt.org.
Abstract
Chronic hepatitis C virus (HCV) infection is a leading cause of hepatocellular carcinoma (HCC) in the U.S. Due to high rates of HCV among baby boomers (born 1945-1965), it was recommended they receive universal screening. This was expanded to all U.S. adults in 2020 due to evidence of increasing rates of chronic HCV in younger adults. An assessment of HCV burden across demographics is crucial to understand the future burden of HCC and target under-screened adults for HCV. Using the OneFlorida Clinical Research Consortium, of more than one million individuals in Florida, all HCV antibody and viral RNA tests completed from 2015 to 2018 were identified. HCV seroprevalence, HCV viral load (active infection), and HCV genotype distribution by risk groups were assessed. Overall, HCV seroprevalence and active infection were highest among White non-Hispanic individuals, males, and baby boomers. However, odds of a positive HCV antibody test were higher among Black non-Hispanic individuals born before 1945 (aOR: 2.74; 95% CI: 1.98-3.78) or 1945-1965 (aOR: 1.46; 95% CI: 1.36-1.56) compared to White non-Hispanic individuals. In contrast, among individuals born after 1965, Black non-Hispanics were less likely than White non-Hispanics to test HCV antibody positive (aOR of 0.5-0.28). A similar age/race pattern was observed for active HCV infection. There was a higher prevalence of genotype 1A and 3 and lower prevalence of 1B in younger adults. Patterns of HCV seroprevalence and active HCV infection identified in our study support the recent shift from age and risk-based screening guidelines to universal adult screening.